D-0215-2026 Class II Ongoing

Recalled by Breckenridge Pharmaceutical, Inc. — Berkeley Heights, NJ

FDA drug recall D-0215-2026 was initiated by Breckenridge Pharmaceutical, Inc. on Nov 24, 2025 and is designated Class II. Reason for recall: CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit The recall status is ongoing. Affected quantity: 3397 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 10, 2025
Initiation Date
Nov 24, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3397 bottles

Product description

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10.

Reason for recall

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Distribution pattern

Nationwide within the United States

Code information

Lot #: 240947C, 240962C, Exp. Date 04/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0215-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0215-2026. Report a data issue: hello@regdatalab.com.